妊娠期甲状腺功能与甲状腺自身免疫与妊娠期糖尿病的关联:系统综述与个体参与者数据Meta分析
该系统综述与个体参与者数据Meta分析纳入25个队列共63548名孕妇,评估妊娠期甲状腺功能指标与妊娠期糖尿病的关联。结果显示孤立性低甲状腺素血症与妊娠期糖尿病风险升高相关(aOR 1.52,95%CI 1.17-1.98),FT4降低及FT3升高、FT3/FT4比值升高亦与风险升高相关,而TSH、甲状腺抗体及其他甲状腺功能异常与妊娠期糖尿病无显著关联。
要点
- 孤立性低甲状腺素血症者妊娠期糖尿病绝对风险6.5% vs 甲状腺功能正常者3.5%,aOR 1.52(95%CI 1.17-1.98)。
- FT4浓度降低与妊娠期糖尿病风险升高呈非线性关联(p<0.0001)。
- TSH、甲状腺抗体及其他甲状腺功能异常与妊娠期糖尿病无显著关联证据。
核心结论
- 妊娠期FT4浓度降低和孤立性低甲状腺素血症与妊娠期糖尿病风险升高相关。
- 结果挑战了亚临床甲状腺功能减退或甲状腺自身免疫是妊娠期糖尿病危险因素的长期观念。
- 需随访研究确定左甲状腺素起始或剂量调整对胰岛素抵抗及降糖治疗的影响程度。
研究设计与样本
- 系统综述与个体参与者数据Meta分析,检索Ovid MEDLINE、EMBASE和Web of Science自建库至2024年12月12日的前瞻性人群队列研究,并公开邀请加入甲状腺与妊娠联盟以识别未发表数据集。
- 排除多胎妊娠、孕前甲状腺疾病或糖尿病、当前使用可能影响甲状腺或血糖水平的药物、不孕治疗史、流产史或死胎史者。
- 最终纳入25个队列共63548名参与者;其中17个队列52632名参与者有TPOAb测量以定义甲状腺疾病实体。
- 采用广义线性混合效应回归模型分析,校正母亲年龄、BMI、吸烟状态、产次、 ethnicity、胎儿性别及采血时孕周。
- 研究方案在PROSPERO预注册(CRD42022371927)。
主要发现
- 在17个队列52632名参与者中,亚临床甲状腺功能减退1687例(3.2%),孤立性低甲状腺素血症1153例(2.2%),妊娠期糖尿病2958例(4.7%)。
- 与甲状腺功能正常相比,孤立性低甲状腺素血症与妊娠期糖尿病风险升高相关(绝对风险6.5%[72/1113] vs 3.5%[1555/44787];aOR 1.52[95%CI 1.17-1.98],p=0.0017;45900名参与者)。
- FT4浓度降低与妊娠期糖尿病风险升高相关(非线性,p<0.0001)。
- FT3浓度升高(aOR 1.18[95%CI 1.10-1.28],p<0.0001)及FT3/FT4比值升高(非线性;p<0.0001)均与妊娠期糖尿病风险升高相关。
- 未发现TSH、甲状腺抗体或其他甲状腺功能检测异常与妊娠期糖尿病的关联证据;主要分析的I²统计量为0-43%;显性甲状腺功能亢进的漏斗图提示可能存在发表偏倚(p=0.049),其他变量的漏斗图未提示。
临床怎么用
- 作者认为妊娠期FT4浓度降低和孤立性低甲状腺素血症与妊娠期糖尿病风险升高相关。
- 作者认为结果支持妊娠期甲状腺功能异常的风险特征以及优化服用左甲状腺素孕妇治疗目标的持续努力。
- 作者指出需随访研究确定左甲状腺素起始或剂量调整对胰岛素抵抗及降糖治疗的影响程度。
局限性
- 显性甲状腺功能亢进的漏斗图提示可能存在发表偏倚(p=0.049)。
- 主要分析的I²统计量为0-43%,提示低至中度异质性。
- 作者指出需随访研究确定左甲状腺素起始或剂量调整对胰岛素抵抗及降糖治疗的影响程度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pregnancy is a state of increased metabolic demand that necessitates major changes in endocrine physiology. Gestational thyroid dysfunction and gestational diabetes are common endocrine conditions of pregnancy that frequently coincide. Although the effects of thyroid hormones on glucose metabolism are well documented, important knowledge gaps remain in terms of the extent and clinical relevance of these effects during pregnancy. The aim of this meta-analysis is to assess the association of thyroid function test results with gestational diabetes and markers of glucose metabolism. METHODS: In this systematic review and individual participant data meta-analysis, we searched Ovid MEDLINE, EMBASE, and Web of Science from database inception to Dec 12, 2024, for prospective population-based cohort studies with individual patient data on thyroid function, gestational diabetes, and measures of glucose homoeostasis during pregnancy. Furthermore, open invitations to join the Consortium on Thyroid and Pregnancy were issued to identify unpublished datasets. We excluded participants with multiple pregnancies; pre-existing thyroid disease or diabetes; current use of medications that could affect thyroid or glucose levels; or a history of infertility treatment, miscarriage, or stillbirth. Exposures were maternal gestational concentrations of thyroid-stimulating hormone (TSH), free T4 (FT4), free T3 (FT3), and total T3; thyroperoxidase antibody positivity; thyroglobulin antibody positivity; and thyroid disease entities (ie, subclinical hypothyroidism, overt and subclinical hyperthyroidism, and isolated hypothyroxinaemia), which were defined according to current guidelines. The primary outcome was presence of gestational diabetes as defined in individual cohorts. Individual participant data were analysed using generalised linear mixed-effects regression models adjusting for maternal age, BMI, smoking status, parity, ethnicity, fetal sex, and gestational age at blood sampling. We preregistered our study protocol with PROSPERO (CRD42022371927). FINDINGS: We identified 638 published studies with our systematic search, of which 21 studies based on 17 cohorts met inclusion criteria; 11 of these prospective cohort studies provided individual participant data, and data from an additional 14 cohorts were added via personal contacts and open invitations, resulting in a study population of 63 548 participants from 25 cohorts after exclusions. Of the 52 632 participants in 17 cohorts with TPOAb measurements available to define thyroid disease entities, 1687 (3·2%) of these participants had subclinical hypothyroidism, 1153 (2·2%) had isolated hypothyroxinaemia, and 2958 (4·7%) had gestational diabetes. Compared with euthyroidism, isolated hypothyroxinaemia was associated with a higher risk of gestational diabetes (absolute risk 6·5% [72 of 1113] for isolated hypothyroxinaemia vs 3·5% [1555 of 44 787] for euthyroidism; adjusted odds ratio [aOR] 1·52 [95% CI 1·17-1·98], p=0·0017; 45 900 participants). A lower FT4 concentration was associated with a higher risk of gestational diabetes (non-linear, p<0·0001). A higher risk of gestational diabetes was found both with a higher FT3 concentration (aOR 1·18 [95%CI 1·10-1·28], p<0·0001) and with a higher FT3-to-FT4 ratio (non-linear; p<0·0001). No evidence was found of associations of TSH, thyroid antibodies, or other thyroid function test abnormalities with gestational diabetes. I2 statistics for the primary analyses ranged from 0-43%, indicating low to moderate heterogeneity. The funnel plot for overt hyperthyroidism indicated a possibility for publication bias (p=0·049), but funnel plots for all other variables did not. INTERPRETATION: A lower FT4 concentration and isolated hypothyroxinaemia during pregnancy are associated with a higher risk of gestational diabetes. Our results challenge the long-standing notion that subclinical hypothyroidism or thyroid autoimmunity are risk factors for gestational diabetes and support both the risk profile for gestational thyroid dysfunction and ongoing efforts on optimisation of treatment targets for pregnant people taking levothyroxine. Follow-up studies are required to establish to what extent levothyroxine initiation or dose adjustments can affect insulin resistance and antihyperglycaemic therapies during pregnancy. FUNDING: The Netherlands Organization for Scientific Research, ZonMw, and the EU Horizon 2020 Program.
引用
- Osinga JAJ, Derakhshan A, Karachaliou M, et al. Association of gestational thyroid function and thyroid autoimmunity with gestational diabetes: a systematic review and individual participant meta-analysis. Lancet Diabetes Endocrinol. 2025. PMID: 40609565. doi:10.1016/S2213-8587(25)00068-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。